Complex of Polymeric Quaternary Ammonium and Anionic Polymers as a New Antimicrobial Agent for Ophthalmic Compositions
Disclosed herein are ophthalmic solutions and methods of using the solutions which comprise a complex of at least one cationic component and an anionic polymer, wherein the complex can be used as an antimicrobial agent. The solutions described have complexes which can be dissolved in aqueous ophthalmic solutions due to both lower charge load and lower total polymer concentrations than commonly taught. The complexes display different antimicrobial profiles than the non-complexed antimicrobial agents.
1 . An ophthalmic composition comprising a complex, said complex formed of a first cationic component, a second cationic component and an anionic component,
wherein said first cationic component comprises at least one polymeric quaternary ammonium compound,
wherein said second cationic component comprises alexidine or a salt thereof,
wherein said anionic component comprises a polymer selected from the group consisting of hyaluronic acid, carboxymethyl cellulose, alginate, carageenan and combinations thereof,
wherein said complex is soluble in an aqueous medium, and
wherein said complex has a synergistic effect against at least one microbe.
2 . The ophthalmic composition of claim 1 wherein said polymeric quaternary ammonium compound is poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-ω-[tris(2-hydroxyethyl)ammonio]-dichloride.
3 . The ophthalmic composition of claim 1 wherein said anionic polymer is hyaluronic acid.
4 . The ophthalmic composition of claim 3 wherein said hyaluronic acid is present from about 0.000001% to about 5% (w/w).
5 . The ophthalmic composition of claim 1 wherein said second cationic compound is selected from the group consisting of alexidine, CPC and alkyldiaminoethylglycine hydrochloride.
6 . The ophthalmic composition of claim 5 wherein said alexidine is present in an amount ranging from about 0.000001% to about 5% (w/w).
7 . The ophthalmic composition of claim 1 wherein said polymeric quaternary ammonium compound comprises from about 0.000001% to about 5% (w/w) of poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-ω-[tris(2-hydroxyethyl)ammonio]-dichloride.
8 . The ophthalmic composition of claim 1 further comprising an ophthalmic adjuvant component selected from the group consisting of a buffer component selected from boric acid, sodium borate, and mixtures thereof, in the range of about 0.01% to about 2% (w/w); a viscosity-inducing component in the range of about 0.01% to about 5% (w/w); a tonicity component comprising about 0.1% to about 1.5% (w/w) sodium chloride; and a combination thereof.
9 . The ophthalmic composition of claim 1 , wherein said ophthalmic composition is a multipurpose solution.
10 . A method of treating an eye or a contact lens comprising contacting said eye or said contact lens with an ophthalmic composition comprising an aqueous medium and an antimicrobial component, said antimicrobial component comprising a complex of a first cationic component, a second cationic and an anionic component,
wherein said first cationic component comprises at least one polymeric quaternary ammonium compound,
wherein said second cationic component comprises alexidine or a salt thereof,
wherein said anionic component comprises a polymer selected from the group consisting of hyaluronic acid, carboxymethyl cellulose, alginate, carageenan and combinations thereof,
wherein said complex is soluble in said aqueous medium, and
wherein said complex has a synergistic effect against at least one microbe.
11 . The method of claim 11 wherein said polymeric quaternary ammonium compound is poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-ω-[tris(2-hydroxyethyl)ammonio]-dichloride.
12 . The method of claim 10 wherein said anionic polymer is hyaluronic acid.
13 . The method of claim 12 wherein said hyaluronic acid is present from about 0.000001% to about 5% (w/w).
14 . The method of claim 10 wherein said second cationic compound is alexidine.
15 . The method of claim 14 wherein said alexidine is present from about 0.000001% to about 5% (w/w).
16 . The method of claim 10 wherein said polymeric quaternary ammonium compound comprises from about 0.000001% to about 5% (w/w) of poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-ω-[tris(2-hydroxyethyl)ammonio]-dichloride.
17 . The method of claim 10 wherein said aqueous medium further comprises an ophthalmic adjuvant component selected from the group consisting of: a buffer component selected from boric acid, sodium borate, and mixtures thereof, in the range of about 0.01% to about 0.5% (w/w); a viscosity-inducing component in the range of about 0.01% to about 5% (w/w); and a tonicity component comprises about 0.4% to about 1.5% (w/w) sodium chloride; or a combination thereof.
18 . An ophthalmic composition comprising a complex, said complex being soluble in an aqueous medium, and said complex comprising poly[(dimethyliminio)-2-butene-1,4-diyl chloride], α-[4-[tris(2-hydroxyethyl)ammonio]-2-butenyl]-ω-[tris(2-hydroxyethyl)ammonio]-dichloride, alexidine, and hyaluronic acid wherein said complex is present in said aqueous medium at a concentration of about 0.00001% to about 3%.